Sponsored by
The phase 1 MAGIC-G1 trial is investigating delivery of MTX110, a new formulation of panobinostat (drug approved to treat multiple myeloma), directly to the tumor site via catheter in recurrent glioblastoma (GBM). Of the first 4 patients treated, two have died (one at 12 and one at 13 months after treatment). The third patient had 6 months progression-free survival (PFS) and is at 13 months overall survival (OS) so far. The fourth patient has not yet had progression and is at 12 months PFS and OS.
While this is a very small, early-stage study, the outcomes so far compare favorably to historic survival rates for recurrent GBM, and the drug appears to have a manageable safety profile. We'll be keeping an eye on this one.